ClinicalTrials.gg
CompletedNCT03564509RAINBOWUpdated Aug 31, 2023

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

A Phase 2 interventional study of FE 999302 (1 μg) and follitropin delta and FE 999302 (2 μg) and follitropin delta in Controlled Ovarian Stimulation, sponsored by Ferring Pharmaceuticals. Completed at 20 sites in 5 countries. Open to female participants aged 30 Years to 42 Years. Per ClinicalTrials.gov, last updated 2023-08-31.

Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
30 Years to 42 Years
Sex
Female
01

Study summary

The purpose of this phase 2 dose-ranging trial is to investigate the effects of FE 999302 on parameters influencing pregnancy rates in women undergoing Controlled Ovarian Stimulation (COS) with follitropin delta in a long gonadotropin releasing hormone (GnRH) agonist protocol.

Furthermore, the study intends:

  • To investigate the safety of FE 999302 in women undergoing COS with follitropin delta in a long GnRH agonist protocol.
  • To investigate the potential immunogenicity of FE 999302 in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.
  • To estimate the impact of body weight on FE 999302 exposure in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.
02

Conditions studied

  • Controlled Ovarian Stimulation

Keywords

  • Human Chorionic Gonadotropin (hCG)
  • Recombinant Human Chorionic Gonadotropin (rhCG)
  • Controlled Ovarian Stimulation (COS)
  • Assisted Reproductive Technologies (ART)
03

In context

Lead sponsor

Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documents signed prior to screening evaluations.
  • In good physical and mental health as judged by the investigator.
  • Anti-Müllerian hormone (AMH) levels at screening of 5.0-35.0 pmol/L (as measured by Elecsys® AMH Plus Immunoassay [Roche Diagnostics] at central laboratory).
  • Pre-menopausal women between the ages of 30 and 42 years. The subjects must be at least 30 years (including the 30th birthday) and no more than 42 years (up to the day before the 43rd birthday) when they sign the informed consent.
  • Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation and/or intracytoplasmic sperm injection using fresh or frozen ejaculated sperm from male partner or sperm donor.
  • Infertility for at least 1 year before screening for subjects less than 35 years or for at least 6 months for subjects greater than equal to (≥)35 years (not applicable in case of tubal or severe male factor infertility).

Exclusion criteria

Exclusion Criteria:

  • Known polycystic ovary syndrome (PCOS) associated with anovulation or known endometriosis stage III-IV (defined by the revised American Society for Reproductive Medicine [ASRM] classification, 1996).
  • One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound after down-regulation prior to randomisation on stimulation day 1 (puncture of cysts is allowed prior to randomisation).
  • Pregnancy (negative pregnancy tests must be documented at screening and prior to start of down-regulation) or to pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
620 participants (actual)

Study arms

  • Experimental
    FE 999302 (1 μg) and follitropin delta

    Drug: FE 999302 (1 μg) and follitropin delta

  • Experimental
    FE 999302 (2 μg) and follitropin delta

    Drug: FE 999302 (2 μg) and follitropin delta

  • Experimental
    FE 999302 (4 μg) and follitropin delta

    Drug: FE 999302 (4 μg) and follitropin delta

  • Experimental
    FE 999302 (8 μg) and follitropin delta

    Drug: FE 999302 (8 μg) and follitropin delta

  • Experimental
    FE 999302 (12 μg) and follitropin delta

    Drug: FE 999302 (12 μg) and follitropin delta

  • Placebo comparator
    Placebo and follitropin delta

    Other: Placebo and follitropin delta

Interventions

  • DrugFE 999302 (1 μg) and follitropin delta

    Drug pages: Ovidrel · Follitropin delta

    Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.

    Also known as: Choriogonadotropin beta

  • DrugFE 999302 (2 μg) and follitropin delta

    Drug pages: Ovidrel · Follitropin delta

    Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

    Also known as: Choriogonadotropin beta

  • DrugFE 999302 (4 μg) and follitropin delta

    Drug pages: Ovidrel · Follitropin delta

    Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

    Also known as: Choriogonadotropin beta

  • DrugFE 999302 (8 μg) and follitropin delta

    Drug pages: Ovidrel · Follitropin delta

    Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

    Also known as: Choriogonadotropin beta

  • DrugFE 999302 (12 μg) and follitropin delta

    Drug pages: Ovidrel · Follitropin delta

    Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

    Also known as: Choriogonadotropin beta

  • OtherPlacebo and follitropin delta

    Daily dose of placebo; individualized follitropin delta dose.

06

What researchers measure

Primary outcomes

  1. Number of good-quality blastocysts on Day 5 after oocyte retrieval

    Quality of blastocysts was assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cell).

    Time frame: On Day 5 after oocyte retrieval

Secondary outcomes

  1. Number of subjects with at least one good-quality blastocyst on Day 5 after oocyte retrieval

    Quality of blastocysts was assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cell).

    Time frame: On Day 5 after oocyte retrieval

  2. Number of subjects with at least two good-quality blastocysts on Day 5 after oocyte retrieval

    Quality of blastocysts was assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cell).

    Time frame: On Day 5 after oocyte retrieval

  3. Number and quality of embryos on Day 3 after oocyte retrieval

    Embryo quality was assessed by cleavage stage and embryo morphology parameters. The total number of embryos and the number of embryos per quality category were reported.

    Time frame: On Day 3 after oocyte retrieval

  4. Number and quality of blastocysts on Day 5 after oocyte retrieval

    Blastocyst quality was assessed by blastocyst expansion and hatching status, blastocyst inner cell mass grading, and trophectoderm grading. The scoring was based on the classification system by Gardner and Schoolcraft, with additional categories for inner cell mass (degenerative or no inner cell mass) and trophectoderm (degenerative or very large cells). The total number of blastocysts and the number of blastocysts per quality category will be reported.

    Time frame: On Day 5 after oocyte retrieval

  5. Changes in serum hormone levels

    Blood samples for analysis of hormone concentrations were drawn at stimulation Day 1, stimulation Day 6, stimulation Day 8, last day of stimulation, and at oocyte retrieval.

    Time frame: Stimulation Day 1 (baseline), stimulation Day 6, stimulation Day 8, end-of-stimulation (up to 20 stimulation days), and oocyte retrieval

  6. Number and size of follicles on stimulation Day 6

    Number and size of follicles assessed using transvaginal ultrasound. The total number of follicles and the number of follicles per size category were reported.

    Time frame: On stimulation Day 6

  7. Number and size of follicles at end-of-stimulation

    Number and size of follicles assessed using transvaginal ultrasound. The total number of follicles and the number of follicles per size category were reported.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  8. Positive beta human chorionic gonadotropin (βhCG) rate

    Proportion of patients with positive blood βhCG confirmed by a blood test.

    Time frame: 13-15 days after blastocyst transfer

  9. Clinical pregnancy rate

    Clinical pregnancy was defined as at least one gestational sac, either intrauterine or ectopic.

    Time frame: 5-6 weeks after blastocyst transfer

  10. Vital pregnancy rate

    Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat, as assessed by transvaginal ultrasound.

    Time frame: 5-6 weeks after blastocyst transfer

  11. Ongoing pregnancy rate

    Ongoing pregnancy was defined as at least one intrauterine viable fetus, assessed using transvaginal or abdominal ultrasound.

    Time frame: 10-11 weeks after blastocyst transfer

  12. Number of oocytes retrieved

    Time frame: On the day of oocyte retrieval

  13. Number of metaphase II oocytes

    Time frame: On the day of oocyte retrieval

  14. Number of fertilised 2 pronuclei (2PN) oocytes

    Time frame: On day 1 after insemination

  15. Total gonadotropin dose

    The daily dose of FE 999302 or placebo, and follitropin delta were recorded.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  16. Total number of stimulation days

    The start and end dates of administration of FE 999302 or placebo, and follitropin delta were recorded.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  17. Incidence of cycle cancellation

    Cycle cancellation due to poor ovarian response or excessive ovarian response.

    Time frame: At end-of-stimulation (up to 20 stimulation days)

  18. Serum concentrations of FE 999302

    Time frame: On stimulation Day 1 (prior to first dose of FE 999302 or placebo), stimulation Day 6, stimulation Day 8, end-of-stimulation (up to 20 stimulation days)

  19. Incidence of ovarian hyperstimulation syndrome (OHSS) (early or late, any grade)

    Early OHSS was defined as OHSS with onset less than equal to 9 days after triggering of final follicular maturation. Late OHSS was defined as OHSS with onset greater than 9 days after triggering of final follicular maturation. All OHSS cases were graded as mild, moderate or severe.

    Time frame: From stimulation Day 1 to end-of-trial (estimated maximum of 4 months from start of stimulation)

  20. Incidence and intensity of adverse events (AEs)

    Time frame: From screening to end-of-trial (estimated maximum of 4 months from start of stimulation)

  21. Changes in circulating levels of clinical chemistry and haematology parameters

    Time frame: At screening, on stimulation Day 1, end-of-stimulation (up to 20 stimulation days), end-of-trial (estimated maximum of 4 months from start of stimulation)

  22. Incidence and intensity of injection site reactions after FE 999302 administration (redness, pain, itching, swelling and bruising) assessed by the subject during the stimulation period

    Time frame: Immediately after injection of FE 999302 or placebo, 30 minutes after injection, and 24 hours after injection

  23. Incidence of treatment-induced anti-FE 999302 antibodies, overall as well as with neutralising capacity

    The proportion of subjects with treatment-induced anti-FE999302 antibodies as well as the proportion of subjects with treatment-induced anti-FE999302 antibodies with neutralizing capacity were reported.

    Time frame: On stimulation Day 1, end-of-stimulation (up to 20 stimulation days), 19-28 days after the last FE999302 or placebo dose

  24. Incidence of multi-fetal gestation

    Time frame: 5 to 6 weeks after transfer

  25. Incidence of biochemical pregnancy

    Biochemical pregnancy was defined as positive βhCG test but no gestational sac was observed on transvaginal ultrasound conducted later, or menstruation is was reported.

    Time frame: Up to 5 to 6 weeks after transfer

  26. Incidence of spontaneous abortion (with and without medical/surgical intervention)

    Spontaneous abortion was defined as positive βhCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there were no viable fetuses observed by ultrasound.

    Time frame: Up to 10 to 11 weeks after transfer

  27. Incidence of ectopic pregnancy (with and without medical/surgical intervention)

    Ectopic pregnancy was defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery.

    Time frame: Up to 5 to 6 weeks after transfer

  28. Incidence of vanishing twins

    Vanishing twin was defined as spontaneous disappearance of an intrauterine gestational sac with or without heart beat in a pregnancy where one viable fetus remained as documented by ultrasound.

    Time frame: Up to 10 to 11 weeks after transfer

07

Study locations

20 sites
  • Universitair Ziekenhuis Gent (UZ Gent)
    Gent, Belgium
  • Universitair Ziekenhuis Brussel
    Jette, Belgium
  • Institut fur Reproduktionsmedizin und Genetik
    Karlovy Vary, Czechia
  • Fertimed
    Olomouc, Czechia
  • GYNEM
    Praha, Czechia
  • IVF CUBE
    Praha, Czechia
  • Aalborg University Hospital
    Aalborg, Denmark
  • Rigshospitalet
    Copenhagen, Denmark
  • Dansk Fertilitetsklinik
    Frederiksberg, Denmark
  • Hvidovre Hospital
    Hvidovre, Denmark
  • Dexeus Woman's Health
    Barcelona, Spain
  • Instituto Valenciano de Infertilidad (IVI) - Bilbao
    Leioa, Spain
  • GINEFIV - Clinica Belen Location
    Madrid, Spain
  • Instituto Valenciano de Infertilidad (IVI) - Madrid
    Madrid, Spain
  • Instituto Valenciano de Infertilidad (IVI) - Sevilla
    Sevilla, Spain
  • Instituto Valenciano de Infertilidad (IVI) - Valencia
    Valencia, Spain
  • Glasgow Royal Infirmary
    Glasgow, United Kingdom
  • Liverpool Women's Hospital
    Liverpool, United Kingdom
  • Guy's and St Thomas' NHS Trust
    London, United Kingdom
  • Kings College (Assisted Conception Unit)
    London, United Kingdom
08

References and documents

Publications

  • Sanchez MF, Larsson P, Serrano MF, Bosch E, Velasco JAG, Lopez ES, Mannaerts B. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol. Reprod Biol Endocrinol. 2023 May 16;21(1):45. doi: 10.1186/s12958-023-01090-w. PubMed 37194068 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Oct 2019, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2018
First posted
Jun 21, 2018
StartActual
May 14, 2018
Primary completionActual
Oct 21, 2019
CompletionActual
Jan 8, 2020
Last update
Aug 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03564509
Responsible party
Sponsor
First posted
Jun 21, 2018
Start date
May 14, 2018
Primary completion
Oct 21, 2019
Completion
Jan 8, 2020
Last update
Aug 31, 2023

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ovidrel · Follitropin delta

Start the discussion